Venrock Healthcare Capital Partners Increases Stake in Enliven Therapeutics to 2.8%

On May 15, 2026, a group of reporting persons led by Venrock Healthcare Capital Partners III, L.P. filed a Schedule 13G/A disclosing an increased position in Enliven Therapeutics, Inc. (ELVN). The reporting group, which includes VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., and managing members Nimish Shah and Bong Koh, collectively reported beneficial ownership of 1,726,331 shares of common stock. This holding represents a 2.8% ownership stake in the company, based on approximately 60.89 million shares outstanding as of March 31, 2026. The filing indicates that the shares are held across several entities: 376,873 shares by VHCP III, 37,695 shares by VHCP Co-Investment III, and 1,311,763 shares by VHCP EG. The reporting persons have certified that these securities were acquired in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer. This amendment reflects an increase from a previously reported 0.0% ownership position.